Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Free Report) crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $4.27 and traded as low as $4.06. Oramed Pharmaceuticals shares last traded at $4.14, with a volume of 84,313 shares traded.
Analysts Set New Price Targets
ORMP has been the subject of a number of research analyst reports. Wall Street Zen raised Oramed Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Weiss Ratings reissued a “hold (c+)” rating on shares of Oramed Pharmaceuticals in a report on Tuesday, September 8th. One research analyst has rated the stock with a Hold rating. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.
View Our Latest Analysis on Oramed Pharmaceuticals
Oramed Pharmaceuticals Stock Up 0.2%
The stock has a market cap of $171.81 million, a PE ratio of 1.00 and a beta of 1.29. The stock has a 50-day moving average of $4.64 and a 200 day moving average of $4.27.
Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.52). On average, equities analysts anticipate that Oramed Pharmaceuticals Inc. will post 1.47 EPS for the current year.
Insider Buying and Selling
In related news, COO Joshua Hexter sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $4.51, for a total transaction of $135,300.00. Following the transaction, the chief operating officer directly owned 1,328,130 shares of the company’s stock, valued at approximately $5,989,866.30. The trade was a 2.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Avraham Gabay sold 20,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $4.51, for a total value of $90,200.00. Following the sale, the chief financial officer owned 861,076 shares of the company’s stock, valued at $3,883,452.76. This represents a 2.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 20.77% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in ORMP. Ritholtz Wealth Management bought a new stake in shares of Oramed Pharmaceuticals in the 1st quarter valued at approximately $529,000. Engineers Gate Manager LP bought a new position in Oramed Pharmaceuticals in the 2nd quarter worth about $61,000. Bank of New York Mellon Corp bought a new stake in shares of Oramed Pharmaceuticals during the 2nd quarter worth about $381,000. Bank of America Corp DE lifted its position in Oramed Pharmaceuticals by 2.7% in the first quarter. Bank of America Corp DE now owns 146,152 shares of the biotechnology company’s stock worth $497,000 after purchasing an additional 3,909 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Oramed Pharmaceuticals by 5.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 158,209 shares of the biotechnology company’s stock worth $538,000 after purchasing an additional 7,738 shares in the last quarter. 12.73% of the stock is currently owned by institutional investors.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc is a biopharmaceutical company focused on developing oral delivery technologies for biologic drugs, including proteins and peptides that are traditionally administered by injection. Its technology is designed to protect these therapies as they pass through the gastrointestinal tract and facilitate absorption into the bloodstream.
The company’s lead programs have included ORMD-0801, an oral insulin candidate developed for the treatment of diabetes, and oral formulations of other peptide-based therapies.
Featured Articles
- Five stocks we like better than Oramed Pharmaceuticals
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
